Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | EIF4E | P06730 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TOP1 | P11387 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 3/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186246 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL11654052 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL11654049 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL18735265 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL6031549 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL13754497 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL18516811 | 0.93 | LMNA (0.66) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL13769963 | 0.90 | LMNA (0.52) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL14160481 | 0.87 | ADRB1 (0.47) | LMNASMN1; SMN2ADORA1ALDH1A1GLA | |
| SCHEMBL23479941 | 0.84 | ADRB3 (0.50) | LMNASMN1; SMN2ADORA1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010111136-A2 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | LMNA 2587/4885SMN1; SMN2 873/4885ADORA1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.